¼¼°èÀÇ ÀÎÅ©·¹Æ¾ °ü·Ã ÀǾàǰ ½ÃÀå : ÀǾàǰ À¯Çüº°, Åõ¿© °æ·Îº°, ÀûÀÀÁõº°, Áö¿ªº°, ±¹°¡º° ºÐ¼® - ½ÃÀå ÀλçÀÌÆ® ¹× Àü¸Á
Global Incretin Based Drugs Market : Analysis By Drug Type, Route of Administration, By Indication, By Region, By Country: Market Insights and Forecast
»óǰÄÚµå : 1390402
¸®¼­Ä¡»ç : Azoth Analytics
¹ßÇàÀÏ : 2023³â 12¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 230 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 2,450 £Ü 3,417,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 2,950 £Ü 4,114,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°è ÀÎÅ©·¹Æ¾ °ü·Ã ÀǾàǰ ½ÃÀå ±Ô¸ð´Â 2022³â 407¾ï 2,000¸¸ ´Þ·¯¿¡¼­ 2029³â ¸»±îÁö 642¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¿¹Ãø ±â°£ÀÎ 2024³âºÎÅÍ 2029³â±îÁö CAGR 6.8%¸¦ ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼¼°èÀûÀ¸·Î 2Çü ´ç´¢º´ÀÇ À¯º´·ü Áõ°¡´Â ÀÎÅ©·¹Æ¾ °ü·Ã ¾àǰ ¼ö¿ä¿¡ Å« ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ´ç´¢º´ À¯º´·ü Áõ°¡´Â ÁÂ½Ä »ýȰ½À°ü, ½Ä½À°üÀÇ º¯È­, °í·ÉÈ­ µî ´Ù¾çÇÑ ¿äÀο¡ ±âÀÎÇÕ´Ï´Ù.

´Ù¸¥ ¸¹Àº Ç×°íÇ÷´çÁ¦¿Í ºñ±³ÇßÀ» ¶§, ÀÎÅ©·¹Æ¾ °ü·Ã ¾à¹°Àº ÀúÇ÷´çÀ̳ª üÁß Áõ°¡ÀÇ À§ÇèÀÌ ¾ø´Â µî ¸î °¡Áö ÁÖ¸ñÇÒ ¸¸ÇÑ ÀÌÁ¡ÀÌ ÀÖÀ¸¸ç, DPP4I¿Í GLP-1RA´Â °íÀ¯ÇÑ È¿´É°ú ³»¾à¼º ÇÁ·ÎÆÄÀÏÀ» º¸¿©Áֱ⠶§¹®¿¡ ÀÇ»ç´Â ȯÀÚÀÇ Áúº´ »óÅÂ(HbA1cÀÇ ¹éºÐÀ²·Î Ç¥½ÃµÊ) HbA1cÀÇ ¹éºÐÀ²·Î Ç¥½ÃµÊ), üÁß, ÀÚ°¡ ÁÖ»çÁ¦¿¡ ´ëÇÑ È¯ÀÚÀÇ ¼±È£µµ µîÀ» °í·ÁÇÏ¿© °¢ ȯÀÚ¿¡°Ô °¡Àå ÀûÇÕÇÑ ¾à¹°À» ¼±ÅÃÇÒ ¼ö ÀÖ½À´Ï´Ù. ºí·Ï¹ö½ºÅÍ ÀǾàǰÀÌ Á¦³×¸¯À¸·Î Ãâ½ÃµÇ°í, Åõ¿© Ƚ¼ö¸¦ ÁÙÀÎ °³¼±µÈ Á¦Á¦°¡ µîÀåÇÔ¿¡ µû¶ó ÀÎÅ©·¹Æ¾ °ü·Ã ¾àǰ ¼ö¿ä´Â Å©°Ô Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ º¸°í¼­´Â ¼¼°è ÀÎÅ©·¹Æ¾ °ü·Ã ÀǾàǰ ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, Áö¿ª ¹× ºÎ¹® ºÐ¼®, ÁÖ¿ä µ¿Çâ°ú ±âȸ µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.

¸ñÂ÷

Á¦1Àå ½ÃÀå ¹è°æ

Á¦2Àå Àü·«Àû Ãßõ »çÇ×

Á¦3Àå ¼¼°èÀÇÀÇ ÀÎÅ©·¹Æ¾ °ü·Ã ÀǾàǰ ½ÃÀå : ½ÇÀû°ú ¿¹Ãø(2018³â-2028³â)

Á¦4Àå ¼¼°èÀÇ ÀÎÅ©·¹Æ¾ °ü·Ã ÀǾàǰ ½ÃÀå, Áö¿ª ºÐ¼®

Á¦5Àå ¾Æ¸Þ¸®Ä«ÀÇ ÀÎÅ©·¹Æ¾ °ü·Ã ÀǾàǰ ½ÃÀå : ½ÇÀû°ú ¿¹Ãø(2018³â-2028³â)

Á¦6Àå À¯·´ÀÇ ÀÎÅ©·¹Æ¾ °ü·Ã ÀǾàǰ ½ÃÀå : ½ÇÀû°ú ¿¹Ãø(2018³â-2028³â)

Á¦7Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÀÎÅ©·¹Æ¾ °ü·Ã ÀǾàǰ ½ÃÀå : ½ÇÀû°ú ¿¹Ãø(2018³â-2028³â)

Á¦8Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÀÎÅ©·¹Æ¾ °ü·Ã ÀǾàǰ ½ÃÀå : ½ÇÀû°ú ¿¹Ãø(2018³â-2028³â)

Á¦9Àå ½ÃÀå ¿ªÇÐ

Á¦10Àå PorterÀÇ Five Forces ºÐ¼®

Á¦11Àå °æÀï Æ÷Áö¼Å´×

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Executive Summary

Azoth Analytics has released a research report titled "Incretin Based Drugs Market (2023 Edition)" which provides a complete analysis of the global Incretin Based Drugs industry in terms of market segmentation By Drug Type (Glucagon-like Peptide-1 Receptor Agonists, Dipeptidyl Peptidase-4 Inhibitors), By Route of Administration (Oral, Injectables) and By Indication (Diabetes, Obesity) for the historical period of 2018-2022, the estimated year of 2023 and the forecast period of 2024-2028.

The research report covers a detailed analysis of the regions (Americas, Europe, APAC, Middle East Africa) and 10 countries (United States, Canada, Germany, United Kingdom, France, Italy, Spain, China, Japan, India). Additionally, the research report presents data including market size, yearly growth & potential analysis, the competitive study of market players, investment opportunities and demand forecast. The research also assesses growth indicators, restraints, supply and demand risk, and other important statistics, as well as a full assessment of current and future market trends that are relevant to the market's evolution.

During the forecast period, 2024-2029, the Global Incretin Based Drugs market is expected to grow at a CAGR of 6.8%. The Global Incretin Based Drugs Market is expected to generate USD 64.28 billion by the end of 2029, up from USD 40.72 Billion in 2022.

Incretin-based drugs are the first-of-its-kind anti-hyperglycemic medications that have been developed by specifically targeting a recognized pathophysiological abnormality in type 2 diabetes. The global increase in the prevalence of type 2 diabetes has a significant impact on the demand for incretin-based drugs. The growing incidence of diabetes can be attributed to various factors, including sedentary lifestyles, poor dietary habits, and the ageing demographic.

In comparison to many other anti-hyperglycemic medications, incretin-based drugs offer some notable benefits, including the lack of an elevated risk of hypoglycemia or weight gain. The DPP4Is and GLP-1RAs exhibit unique efficacy and tolerability profiles, providing physicians with the opportunity to choose the most suitable medication for each patient, taking into account factors such as disease status (as indicated by HbA1c percentage), body weight, and patient preference for self-administered injectable drugs. The demand for Incretin-based drugs is expected to grow exponentially as the blockbuster drugs in the market become accessible in generic form and as upgraded formulations with reduced dosing frequency are introduced.

Scope of the Report

Table of Contents

1. Market Background

2. Strategic Recommendations

3. Global Incretin Based Drugs Market: Historic and Forecast (2018-2028)

4. Global Incretin Based Drugs Market, Region Analysis

5. Americas Incretin Based Drugs Market: Historic and Forecast (2018-2028)

6. Europe Incretin Based Drugs Market: Historic and Forecast (2018-2028)

7. Asia-Pacific Incretin Based Drugs Market: Historic and Forecast (2018-2028)

8. Middle-East & Africa Incretin Based Drugs Market: Historic and Forecast (2018-2028)

9. Market Dynamics

10. Porter's Five Forces Analysis

11. Competitive Positioning

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â